- 中文名称
Anti-Human FGF-22
- 英文名字
- Anti-Human FGF-22
- 供应商
- ReliaTech
- 产品货号
- 101-M407
- 产品报价
- ￥询价/100ug
- 产品说明书
- 点击查看
- 购买方式
- 90%产品中国有现货库存。银行转账、电汇、支票、现金，在线支付宝及网银支付，或直接与我们电话联系400-6800-868
- 产品新闻
- 背景资料
- Fibroblast growth factor 22 (FGF22) is a 23 kDa, non-glycosylated member of the FGF7 subfamily, from the FGF family of heparin-binding growth factors. The human FGF22 precursor is 170 amino acids (aa) in length, and contains a 22 aa signal sequence with a 148 aa mature region (46). The mature region shows a centrally-placed, 120 aa β-trefoil region (aa 43-168) that is characteristic of all FGF family members. Human FGF22 potentially has one alternate splice form. This isoform is 129 aa in length, and shows a 31 aa substitution for the first N-terminal 72 aa of the standard, or long, form. There is no information related to its possible function. Mature human FGF22 is 86% aa identical to mouse FGF22, with the mouse molecule showing a 9 aa deletion at the N-terminus. FGF 22 is synthesized by at least three cell types; keratinocytes, neurons, and skeletal muscle myotubes. In neurons and myotubes, FGF22 is presumed to function as an organizer of the presynaptic apparatus. Expressed by post-synaptic (or target) cells, FGF22 is believed to bind to FGF R2b on the surface of innervating processes, resulting in synaptic vesicle clustering, organization, and neurite branching. Although FGF22 is assumed to be secreted, little can be found in expressing cell culture media. Presumably, it is bound to 34 kDa FGFBP1, which is a molecule described as typically associated with cell membrane proteoglycans. Thus, following secretion, FGF22 could quickly be immobilized by FGFBP1, only to be released at a later time, or aided by FGFBP1 in its interaction with FGF R2b.
- 应用类型
- WB, IHC (P)
- 免疫原
- 该Anti-Human FGF-22的详细信息查看ReliaTech提供的产品说明书。
- 来源宿主
- 该Anti-Human FGF-22的详细信息查看ReliaTech提供的产品说明书。
- 反应性
- 该Anti-Human FGF-22的详细信息查看ReliaTech提供的产品说明书。
- 保存建议
- 该Anti-Human FGF-22的详细信息查看ReliaTech提供的产品说明书。溶解建议：Centrifuge vial prior to opening. Reconstitute the antibody with 500 µl sterile PBS and the final concentration is 200 µg/ml.
- 其他
- ReliaTech全称为受体配体技术有限公司 (Receptor Ligand Technologies GmbH)，1999年成立，总部位于德国不伦瑞克，是一家后基因组生物技术公司。ReliaTech主要专注于受体和配体的发现与研究。此外，ReliaTech也开发应用于血管与淋巴管生成研究的相关高品质试剂。目前ReliaTech提供近2800款产品，产品线主要包括重组蛋白(细胞因子、生长因子、可溶性受体)、抗体、ELISA试剂盒等。
- 注意
-
该页面的中文产品信息的翻译，仅供参考。准确的产品信息请以厂家的英文说明书为准。下单前，请浏览说明书确认。
-
